ARVN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 43.91% compared to Arvinas's net margin of -9.67%. Arvinas's return on equity of -7.72% beat Alnylam Pharmaceuticals's return on equity of --.

Arvinas has a consensus price target of $22.36, signalling upside risk potential of 228.36%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.56 which suggests that it could grow by 24.08%. Given that Arvinas has higher upside potential than Alnylam Pharmaceuticals, analysts believe Arvinas is more attractive than Alnylam Pharmaceuticals.

Arvinas has a beta of 2.215, which suggesting that the stock is 121.499% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $188.8M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Arvinas's net income of $82.9M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Arvinas's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.15x versus 14.14x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of 43.91% compared to Arvinas's net margin of -87.96%. Arvinas's return on equity of -7.72% beat Fortress Biotech's return on equity of --.

Arvinas has a consensus price target of $22.36, signalling upside risk potential of 228.36%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 807.3%. Given that Fortress Biotech has higher upside potential than Arvinas, analysts believe Fortress Biotech is more attractive than Arvinas.

Arvinas has a beta of 2.215, which suggesting that the stock is 121.499% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Arvinas quarterly revenues are $188.8M, which are larger than Fortress Biotech quarterly revenues of $14.6M. Arvinas's net income of $82.9M is higher than Fortress Biotech's net income of -$12.9M. Notably, Arvinas's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.15x versus 0.47x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of 43.91% compared to Arvinas's net margin of -17.31%. Arvinas's return on equity of -7.72% beat Amicus Therapeutics's return on equity of -17.7%.

Arvinas has a consensus price target of $22.36, signalling upside risk potential of 228.36%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 160.17%. Given that Arvinas has higher upside potential than Amicus Therapeutics, analysts believe Arvinas is more attractive than Amicus Therapeutics.

Arvinas has a beta of 2.215, which suggesting that the stock is 121.499% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $188.8M, which are larger than Amicus Therapeutics quarterly revenues of $125.2M. Arvinas's net income of $82.9M is higher than Amicus Therapeutics's net income of -$21.7M. Notably, Arvinas's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.15x versus 3.42x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 43.91% compared to Arvinas's net margin of 21.63%. Arvinas's return on equity of -7.72% beat Pfizer's return on equity of 8.72%.

Arvinas has a consensus price target of $22.36, signalling upside risk potential of 228.36%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 27.33%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Arvinas has a beta of 2.215, which suggesting that the stock is 121.499% more volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Arvinas pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Arvinas quarterly revenues are $188.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Arvinas's net income of $82.9M is lower than Pfizer's net income of $3B. Notably, Arvinas's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.15x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.